PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Both companies show declining cash positions (-32.96% vs GNPX's -49.68%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Cash + STI yoy 0.5-0.75x GNPX's -49.68%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
0.5-0.75x GNPX's -47.98%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-7.82%
Below half GNPX's 31.87%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
≥ 1.5x GNPX's 58.70%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
1.25-1.5x GNPX's -21.03%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-28.35%
Less than half of GNPX's 20.89%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
Less than half of GNPX's 37.37%. David Dodd sees fewer expansions in other current obligations.
-23.54%
Less than half of GNPX's 23.89%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
Less than half of GNPX's 23.89%. David Dodd sees far fewer liability expansions relative to competitor.
2.39%
Less than half of GNPX's 5.11%. David Dodd sees fewer share issuances vs. competitor.
-4.88%
0.5-0.75x GNPX's -7.93%. Martin Whitman is wary of weaker retention or lower profitability.
-7.49%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
1.25-1.5x GNPX's -27.91%. Bruce Berkowitz notes an above-average equity expansion.
-28.88%
1.25-1.5x GNPX's -21.03%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
50-75% of GNPX's 49.68%. Bruce Berkowitz notes comparatively lower net debt expansion.